Over-expression of CXCR4 has been identified as a promising prognostic biomarker for gastrointestinal and acute myeloid leukemia, among many other tumor types (Du et al., 2019; Jiang et al., 2019). This evidence concerns the gene CXCR4 and neoplasm.